{"transactions":[{"id":737689,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-15T21:26:32.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":38040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. \"Date of Grant\" shall mean June 12, 2026."}],"balance_after":38040,"derivative":{"exercise_price":4.16,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":38040},"source":{"system":"sec-edgar","filing":"0001680329-26-000005","document":"form4-06152026_090628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000168032926000005/form4-06152026_090628.xml","form_type":"4"}},{"id":947930,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T22:20:23.000Z","date":"2026-01-05","kind":"exercise","planned":true,"acquired":false,"shares":734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":46.54,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":734},"source":{"system":"sec-edgar","filing":"0001680329-26-000002","document":"form4-01062026_050117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032926000002/form4-01062026_050117.xml","form_type":"4"}},{"id":947929,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T22:20:23.000Z","date":"2026-01-02","kind":"grant","planned":true,"acquired":true,"shares":3475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026."}],"balance_after":3475,"derivative":{"exercise_price":76.74,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":3475},"source":{"system":"sec-edgar","filing":"0001680329-26-000002","document":"form4-01062026_050117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032926000002/form4-01062026_050117.xml","form_type":"4"}},{"id":947928,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:20:23.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":734,"price":76,"value":55784.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":10666,"source":{"system":"sec-edgar","filing":"0001680329-26-000002","document":"form4-01062026_050117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032926000002/form4-01062026_050117.xml","form_type":"4"}},{"id":947927,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:20:23.000Z","date":"2026-01-05","kind":"exercise","planned":true,"acquired":true,"shares":734,"price":46.54,"value":34160.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":11400,"source":{"system":"sec-edgar","filing":"0001680329-26-000002","document":"form4-01062026_050117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032926000002/form4-01062026_050117.xml","form_type":"4"}},{"id":947926,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:20:23.000Z","date":"2026-01-02","kind":"grant","planned":true,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027."}],"balance_after":10666,"source":{"system":"sec-edgar","filing":"0001680329-26-000002","document":"form4-01062026_050117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032926000002/form4-01062026_050117.xml","form_type":"4"}},{"id":979463,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-05T22:20:04.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":false,"shares":733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025."}],"balance_after":734,"derivative":{"exercise_price":46.54,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":733},"source":{"system":"sec-edgar","filing":"0001680329-25-000014","document":"form4-12052025_051201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000014/form4-12052025_051201.xml","form_type":"4"}},{"id":979462,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-05T22:20:04.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":733,"price":78.62,"value":57628.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":6666,"source":{"system":"sec-edgar","filing":"0001680329-25-000014","document":"form4-12052025_051201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000014/form4-12052025_051201.xml","form_type":"4"}},{"id":979461,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-05T22:20:04.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":true,"shares":733,"price":46.54,"value":34113.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":7399,"source":{"system":"sec-edgar","filing":"0001680329-25-000014","document":"form4-12052025_051201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000014/form4-12052025_051201.xml","form_type":"4"}},{"id":989120,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-25T22:20:05.000Z","date":"2025-11-21","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":51.16,"expiration_date":"2030-01-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001680329-25-000012","document":"form4-11252025_051101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000012/form4-11252025_051101.xml","form_type":"4"}},{"id":989119,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T22:20:05.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":79.5,"value":795000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025"}],"balance_after":6666,"source":{"system":"sec-edgar","filing":"0001680329-25-000012","document":"form4-11252025_051101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000012/form4-11252025_051101.xml","form_type":"4"}},{"id":989118,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T22:20:05.000Z","date":"2025-11-21","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":51.16,"value":511600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025"}],"balance_after":16666,"source":{"system":"sec-edgar","filing":"0001680329-25-000012","document":"form4-11252025_051101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000012/form4-11252025_051101.xml","form_type":"4"}},{"id":999311,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-14T22:20:05.000Z","date":"2025-11-12","kind":"exercise","planned":true,"acquired":false,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025."}],"balance_after":1467,"derivative":{"exercise_price":46.54,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001680329-25-000010","document":"form4-11142025_051101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000010/form4-11142025_051101.xml","form_type":"4"}},{"id":999310,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T22:20:05.000Z","date":"2025-11-12","kind":"sale","planned":true,"acquired":false,"shares":7333,"price":74.5,"value":546308.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":6666,"source":{"system":"sec-edgar","filing":"0001680329-25-000010","document":"form4-11142025_051101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000010/form4-11142025_051101.xml","form_type":"4"}},{"id":999309,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T22:20:05.000Z","date":"2025-11-12","kind":"exercise","planned":true,"acquired":true,"shares":7333,"price":46.54,"value":341277.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":13999,"source":{"system":"sec-edgar","filing":"0001680329-25-000010","document":"form4-11142025_051101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000010/form4-11142025_051101.xml","form_type":"4"}},{"id":1010874,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-31T21:20:05.000Z","date":"2025-10-30","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":38.1,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001680329-25-000008","document":"form4-10312025_051001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000008/form4-10312025_051001.xml","form_type":"4"}},{"id":1010873,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T21:20:05.000Z","date":"2025-10-30","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":69.5,"value":834000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":6666,"source":{"system":"sec-edgar","filing":"0001680329-25-000008","document":"form4-10312025_051001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000008/form4-10312025_051001.xml","form_type":"4"}},{"id":1010872,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T21:20:05.000Z","date":"2025-10-30","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":38.1,"value":457200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":18666,"source":{"system":"sec-edgar","filing":"0001680329-25-000008","document":"form4-10312025_051001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000008/form4-10312025_051001.xml","form_type":"4"}},{"id":1010871,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T21:20:05.000Z","date":"2025-10-30","kind":"sale","planned":true,"acquired":false,"shares":3666,"price":69.5,"value":254787.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":6666,"source":{"system":"sec-edgar","filing":"0001680329-25-000008","document":"form4-10312025_051001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000008/form4-10312025_051001.xml","form_type":"4"}},{"id":1022479,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"exercise","planned":true,"acquired":false,"shares":8650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":8650},"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022478,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"exercise","planned":true,"acquired":false,"shares":6912,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":33.02,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":6912},"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022477,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":33.63,"expiration_date":"2033-01-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022476,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":1884,"price":66.89,"value":126020.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":10332,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022475,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":4037,"price":66.1,"value":266845.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.46 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":12216,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022474,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":2729,"price":65.05,"value":177521.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":16253,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022473,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"exercise","planned":true,"acquired":true,"shares":8650,"price":33.63,"value":290899.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":18982,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022472,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":66.93,"value":107088.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":10332,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022471,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":3149,"price":66.11,"value":208180.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":11932,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022470,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":2163,"price":65.02,"value":140638.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15081,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022469,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"exercise","planned":true,"acquired":true,"shares":6912,"price":33.02,"value":228234.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":17244,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022468,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":2381,"price":66.87,"value":159217.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.50 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":10332,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022467,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":4591,"price":66.09,"value":303419.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":12713,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022466,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":3028,"price":65.09,"value":197092.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":17304,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1022465,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:20:15.000Z","date":"2025-10-03","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":39.42,"value":394200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":20332,"source":{"system":"sec-edgar","filing":"0001680329-25-000006","document":"form4-10072025_051012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000006/form4-10072025_051012.xml","form_type":"4"}},{"id":1039727,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-16T21:00:07.000Z","date":"2025-09-11","kind":"exercise","planned":true,"acquired":false,"shares":837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":837},"source":{"system":"sec-edgar","filing":"0001680329-25-000004","document":"form4-09162025_050903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000004/form4-09162025_050903.xml","form_type":"4"}},{"id":1039726,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-16T21:00:07.000Z","date":"2025-09-11","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":25.69,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001680329-25-000004","document":"form4-09162025_050903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000004/form4-09162025_050903.xml","form_type":"4"}},{"id":1039725,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T21:00:07.000Z","date":"2025-09-11","kind":"sale","planned":true,"acquired":false,"shares":837,"price":59.5,"value":49801.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":10332,"source":{"system":"sec-edgar","filing":"0001680329-25-000004","document":"form4-09162025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000004/form4-09162025_050903.xml","form_type":"4"}},{"id":1039724,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T21:00:07.000Z","date":"2025-09-11","kind":"exercise","planned":true,"acquired":true,"shares":837,"price":33.63,"value":28148.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":11169,"source":{"system":"sec-edgar","filing":"0001680329-25-000004","document":"form4-09162025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000004/form4-09162025_050903.xml","form_type":"4"}},{"id":1039723,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T21:00:07.000Z","date":"2025-09-11","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":59.5,"value":595000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":10332,"source":{"system":"sec-edgar","filing":"0001680329-25-000004","document":"form4-09162025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000004/form4-09162025_050903.xml","form_type":"4"}},{"id":1039722,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T21:00:07.000Z","date":"2025-09-11","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":25.69,"value":256900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":20332,"source":{"system":"sec-edgar","filing":"0001680329-25-000004","document":"form4-09162025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000004/form4-09162025_050903.xml","form_type":"4"}},{"id":1039721,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T21:00:07.000Z","date":"2025-09-11","kind":"sale","planned":true,"acquired":false,"shares":1334,"price":59.5,"value":79373.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":10332,"source":{"system":"sec-edgar","filing":"0001680329-25-000004","document":"form4-09162025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000004/form4-09162025_050903.xml","form_type":"4"}},{"id":1039720,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T21:00:07.000Z","date":"2025-09-11","kind":"sale","planned":true,"acquired":false,"shares":3534,"price":59.5,"value":210273.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025."}],"balance_after":11666,"source":{"system":"sec-edgar","filing":"0001680329-25-000004","document":"form4-09162025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000168032925000004/form4-09162025_050903.xml","form_type":"4"}},{"id":1109688,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-16T20:54:40.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":40006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. \"Date of Grant\" shall mean June 12, 2025."}],"balance_after":40006,"derivative":{"exercise_price":2.04,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":40006},"source":{"system":"sec-edgar","filing":"0001415889-25-017410","document":"form4-06162025_080636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000141588925017410/form4-06162025_080636.xml","form_type":"4"}},{"id":1308711,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T22:20:27.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":8800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025."}],"balance_after":8800,"derivative":{"exercise_price":46.54,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":8800},"source":{"system":"sec-edgar","filing":"0001415889-25-001025","document":"form4-01072025_050122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588925001025/form4-01072025_050122.xml","form_type":"4"}},{"id":1308710,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-07T22:20:27.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026."}],"balance_after":15200,"source":{"system":"sec-edgar","filing":"0001415889-25-001025","document":"form4-01072025_050122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588925001025/form4-01072025_050122.xml","form_type":"4"}},{"id":1478852,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:09:24.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":45832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. \"Date of Grant\" shall mean June 12, 2024."}],"balance_after":45832,"derivative":{"exercise_price":1.7,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45832},"source":{"system":"sec-edgar","filing":"0001415889-24-016870","document":"form4-06142024_080619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000141588924016870/form4-06142024_080619.xml","form_type":"4"}},{"id":1494753,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2024-06-03T20:30:27.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2024 and is scheduled to vest in full on  May 30, 2025"}],"balance_after":25000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001650664-24-000060","document":"wk-form4_1717446617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000060/wk-form4_1717446617.xml","form_type":"4"}},{"id":1639136,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T21:10:46.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024."}],"balance_after":10000,"derivative":{"exercise_price":25.69,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-004100","document":"form4-02162024_040209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588924004100/form4-02162024_040209.xml","form_type":"4"}},{"id":1639135,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-16T21:10:46.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025."}],"balance_after":11200,"source":{"system":"sec-edgar","filing":"0001415889-24-004100","document":"form4-02162024_040209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588924004100/form4-02162024_040209.xml","form_type":"4"}},{"id":1849370,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T00:19:58.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":28255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant.  \"Date of Grant\" shall mean June 15, 2023."}],"balance_after":28255,"derivative":{"exercise_price":8.2,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":28255},"source":{"system":"sec-edgar","filing":"0001209191-23-038663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000120919123038663/doc4.xml","form_type":"4"}},{"id":1866069,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T20:30:40.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024."}],"balance_after":25000,"derivative":{"exercise_price":9.55,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009237","document":"form4-06052023_040625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588923009237/form4-06052023_040625.xml","form_type":"4"}},{"id":1880182,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"exercise","planned":true,"acquired":false,"shares":1402,"price":33.63,"value":47149.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Currently exercisable."}],"balance_after":8650,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":1402},"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880181,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"exercise","planned":true,"acquired":false,"shares":1093,"price":33.02,"value":36090.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Currently exercisable."}],"balance_after":6912,"derivative":{"exercise_price":33.02,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":1093},"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880180,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"exercise","planned":true,"acquired":false,"shares":157,"price":33.63,"value":5279.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Currently exercisable."}],"balance_after":837,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":157},"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880179,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":false,"shares":3948,"price":33.63,"value":132771.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Currently exercisable."}],"balance_after":10052,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":3948},"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880178,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":false,"shares":2995,"price":33.02,"value":98894.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Currently exercisable."}],"balance_after":8005,"derivative":{"exercise_price":33.02,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":2995},"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880177,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":false,"shares":173,"price":33.63,"value":5817.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Currently exercisable."}],"balance_after":994,"derivative":{"exercise_price":33.63,"expiration_date":"2028-12-13","underlying":"Common Stock","underlying_shares":173},"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880176,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":1402,"price":59.5378,"value":83471.9956,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.71 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7200,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880175,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"exercise","planned":true,"acquired":true,"shares":1402,"price":33.63,"value":47149.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":8602,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880174,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":1093,"price":59.532,"value":65068.476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7200,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880173,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"exercise","planned":true,"acquired":true,"shares":1093,"price":33.02,"value":36090.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":8293,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880172,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"sale","planned":true,"acquired":false,"shares":157,"price":59.5171,"value":9344.1847,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7200,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880171,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-23","kind":"exercise","planned":true,"acquired":true,"shares":157,"price":33.63,"value":5279.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":7357,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880170,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"sale","planned":true,"acquired":false,"shares":3948,"price":59.5313,"value":235029.5724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7200,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880169,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":true,"shares":3948,"price":33.63,"value":132771.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":11148,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880168,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"sale","planned":true,"acquired":false,"shares":2995,"price":59.5335,"value":178302.8325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7200,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880167,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":true,"shares":2995,"price":33.02,"value":98894.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":10195,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880166,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"sale","planned":true,"acquired":false,"shares":173,"price":59.5242,"value":10297.6866,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7200,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1880165,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T20:12:25.000Z","date":"2023-05-22","kind":"exercise","planned":true,"acquired":true,"shares":173,"price":33.63,"value":5817.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":7373,"source":{"system":"sec-edgar","filing":"0001415889-23-008704","document":"form4-05242023_080557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923008704/form4-05242023_080557.xml","form_type":"4"}},{"id":1914368,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-25T20:08:23.000Z","date":"2023-04-21","kind":"sale","planned":true,"acquired":false,"shares":100,"price":55.57,"value":5557.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."}],"balance_after":7200,"source":{"system":"sec-edgar","filing":"0001415889-23-006831","document":"form4-04252023_080413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923006831/form4-04252023_080413.xml","form_type":"4"}},{"id":1914367,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-25T20:08:23.000Z","date":"2023-04-21","kind":"sale","planned":true,"acquired":false,"shares":4228,"price":55.0381,"value":232701.0868,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.50 to $55.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7300,"source":{"system":"sec-edgar","filing":"0001415889-23-006831","document":"form4-04252023_080413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923006831/form4-04252023_080413.xml","form_type":"4"}},{"id":2059220,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-09T21:13:21.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023."}],"balance_after":10000,"derivative":{"exercise_price":39.42,"expiration_date":"2033-01-04","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-23-000671","document":"form4-01092023_090113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923000671/form4-01092023_090113.xml","form_type":"4"}},{"id":2059219,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-09T21:13:21.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024."}],"balance_after":11528,"source":{"system":"sec-edgar","filing":"0001415889-23-000671","document":"form4-01092023_090113.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000141588923000671/form4-01092023_090113.xml","form_type":"4"}},{"id":2227496,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:28:45.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18573,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant.  \"Date of Grant\" shall mean June 15, 2022."}],"balance_after":18573,"derivative":{"exercise_price":13.46,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":18573},"source":{"system":"sec-edgar","filing":"0001209191-22-037893","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000120919122037893/doc4.xml","form_type":"4"}},{"id":2233633,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T20:30:40.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023."}],"balance_after":25000,"derivative":{"exercise_price":12.31,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-22-006493","document":"form4-06132022_040629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588922006493/form4-06132022_040629.xml","form_type":"4"}},{"id":2438148,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2022-01-11T21:12:15.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022."}],"balance_after":12000,"derivative":{"exercise_price":38.1,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001179110-22-000389","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911022000389/edgar.xml","form_type":"4"}},{"id":2438147,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T21:12:15.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023."}],"balance_after":7528,"source":{"system":"sec-edgar","filing":"0001179110-22-000389","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911022000389/edgar.xml","form_type":"4"}},{"id":2573114,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-09-10T20:47:09.000Z","date":"2021-09-08","kind":"grant","acquired":true,"shares":16486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the Initial Award shall be fully vested on the three year anniversary of the grant date. The grant date is September 8, 2021."}],"balance_after":16486,"derivative":{"exercise_price":27.67,"expiration_date":"2031-09-08","underlying":"Common Stock","underlying_shares":16486},"source":{"system":"sec-edgar","filing":"0000899243-21-035558","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000089924321035558/doc4.xml","form_type":"4"}},{"id":2575573,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-08T20:33:10.000Z","date":"2021-09-03","kind":"grant","acquired":true,"shares":13736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 3, 2021 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on September 3, 2022 through September 3, 2024."}],"balance_after":13736,"derivative":{"exercise_price":68.25,"expiration_date":"2031-09-02","underlying":"Common Stock","underlying_shares":13736},"source":{"system":"sec-edgar","filing":"0001179110-21-008671","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000117911021008671/edgar.xml","form_type":"4"}},{"id":2630288,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2021-07-19T17:38:22.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":66950,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":35.5,"underlying":"Common Stock","underlying_shares":66950},"source":{"system":"sec-edgar","filing":"0001562180-21-004984","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004984/primarydocument.xml","form_type":"4"}},{"id":2630287,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-19T17:38:22.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":80971,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":6.61,"underlying":"Common Stock","underlying_shares":80971},"source":{"system":"sec-edgar","filing":"0001562180-21-004984","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004984/primarydocument.xml","form_type":"4"}},{"id":2630286,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-19T17:38:22.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":17666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":7.6,"underlying":"Common Stock","underlying_shares":17666},"source":{"system":"sec-edgar","filing":"0001562180-21-004984","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004984/primarydocument.xml","form_type":"4"}},{"id":2630285,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-19T17:38:22.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":11777,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":8.04,"underlying":"Common Stock","underlying_shares":11777},"source":{"system":"sec-edgar","filing":"0001562180-21-004984","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004984/primarydocument.xml","form_type":"4"}},{"id":2630284,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-19T17:38:22.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":73428,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":8.76,"underlying":"Common Stock","underlying_shares":73428},"source":{"system":"sec-edgar","filing":"0001562180-21-004984","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004984/primarydocument.xml","form_type":"4"}},{"id":2630283,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-19T17:38:22.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":37527,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":11.5,"underlying":"Common Stock","underlying_shares":37527},"source":{"system":"sec-edgar","filing":"0001562180-21-004984","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004984/primarydocument.xml","form_type":"4"}},{"id":2630282,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-19T17:38:22.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":36.06,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001562180-21-004984","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004984/primarydocument.xml","form_type":"4"}},{"id":2839119,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-23T17:58:29.000Z","date":"2021-02-22","kind":"exercise","acquired":false,"shares":6260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022."}],"balance_after":11777,"derivative":{"exercise_price":8.04,"expiration_date":"2028-04-22","underlying":"Common Stock","underlying_shares":6260},"source":{"system":"sec-edgar","filing":"0001562180-21-001509","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001509/primarydocument.xml","form_type":"4"}},{"id":2839118,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-23T17:58:29.000Z","date":"2021-02-19","kind":"exercise","acquired":false,"shares":4010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022."}],"balance_after":18037,"derivative":{"exercise_price":8.04,"expiration_date":"2028-04-22","underlying":"Common Stock","underlying_shares":4010},"source":{"system":"sec-edgar","filing":"0001562180-21-001509","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001509/primarydocument.xml","form_type":"4"}},{"id":2839117,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-23T17:58:29.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":6260,"price":37.5996,"value":235373.496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $37.50 to $37.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-21-001509","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001509/primarydocument.xml","form_type":"4"}},{"id":2839116,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-23T17:58:29.000Z","date":"2021-02-22","kind":"exercise","acquired":true,"shares":6260,"price":8.04,"value":50330.4,"ownership":{"direct":true},"balance_after":6260,"source":{"system":"sec-edgar","filing":"0001562180-21-001509","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001509/primarydocument.xml","form_type":"4"}},{"id":2839115,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-23T17:58:29.000Z","date":"2021-02-19","kind":"sale","acquired":false,"shares":4010,"price":37.7102,"value":151217.902,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $37.54 to $37.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-21-001509","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001509/primarydocument.xml","form_type":"4"}},{"id":2839114,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-23T17:58:29.000Z","date":"2021-02-19","kind":"exercise","acquired":true,"shares":4010,"price":8.04,"value":32240.4,"ownership":{"direct":true},"balance_after":4010,"source":{"system":"sec-edgar","filing":"0001562180-21-001509","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001509/primarydocument.xml","form_type":"4"}},{"id":2846003,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-19T16:17:07.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022."}],"balance_after":22047,"derivative":{"exercise_price":8.04,"expiration_date":"2028-04-22","underlying":"Common Stock","underlying_shares":1100},"source":{"system":"sec-edgar","filing":"0001562180-21-001319","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001319/primarydocument.xml","form_type":"4"}},{"id":2846002,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-19T16:17:07.000Z","date":"2021-02-17","kind":"exercise","acquired":false,"shares":410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022."}],"balance_after":23147,"derivative":{"exercise_price":8.04,"expiration_date":"2028-04-22","underlying":"Common Stock","underlying_shares":410},"source":{"system":"sec-edgar","filing":"0001562180-21-001319","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001319/primarydocument.xml","form_type":"4"}},{"id":2846001,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T16:17:07.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":1100,"price":37.5846,"value":41343.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $37.50 to $37.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-21-001319","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001319/primarydocument.xml","form_type":"4"}},{"id":2846000,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T16:17:07.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":1100,"price":8.04,"value":8844.0,"ownership":{"direct":true},"balance_after":1100,"source":{"system":"sec-edgar","filing":"0001562180-21-001319","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001319/primarydocument.xml","form_type":"4"}},{"id":2845999,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T16:17:07.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":410,"price":37.5557,"value":15397.837,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $37.50 to $37.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-21-001319","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001319/primarydocument.xml","form_type":"4"}},{"id":2845998,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-19T16:17:07.000Z","date":"2021-02-17","kind":"exercise","acquired":true,"shares":410,"price":8.04,"value":3296.4,"ownership":{"direct":true},"balance_after":410,"source":{"system":"sec-edgar","filing":"0001562180-21-001319","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001319/primarydocument.xml","form_type":"4"}},{"id":2849863,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-18T16:51:53.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":66950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2021, and the shares underlying the option vest in equal quarterly installments through February 16, 2025, subject to continued service."}],"balance_after":66950,"derivative":{"exercise_price":35.5,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":66950},"source":{"system":"sec-edgar","filing":"0001562180-21-001261","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021001261/primarydocument.xml","form_type":"4"}},{"id":2912638,"issuer":{"id":3803,"kind":"organization","name":"PTC THERAPEUTICS, INC.","symbol":"PTCT"},"owners":[{"id":38135,"kind":"person","name":"Reeve Emma","position":1,"cik":"0001680329","reported_name":"Reeve Emma","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2021-01-08T22:10:40.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 6, 2021 and vests over one year in twelve equal monthly installments, commencing on February 6, 2021."}],"balance_after":10000,"derivative":{"exercise_price":66.49,"expiration_date":"2031-01-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-21-000465","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070081/000117911021000465/edgar.xml","form_type":"4"}}],"next_cursor":"2021-01-08T22:10:40.000000Z,2912638"}